128 related articles for article (PubMed ID: 36787514)
21. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
23. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
24. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
25. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
[TBL] [Abstract][Full Text] [Related]
26. Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy.
Liu Y; Zheng M; Jiao M; Yan C; Xu S; Du Q; Morsch M; Yin J; Shi B
Biomaterials; 2021 Sep; 276():121036. PubMed ID: 34329919
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Reprogramming of Glioblastoma Cells during HCMV Infection Induces Secretome-Mediated Paracrine Effects in the Microenvironment.
Harrison MAA; Hochreiner EM; Benjamin BP; Lawler SE; Zwezdaryk KJ
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062307
[TBL] [Abstract][Full Text] [Related]
28. Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells.
Bruun J; Larsen TB; Jølck RI; Eliasen R; Holm R; Gjetting T; Andresen TL
Int J Nanomedicine; 2015; 10():5995-6008. PubMed ID: 26451106
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
30. Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma.
Chen S; Li X; Wang H; Chen G; Zhou Y
Biochem Biophys Res Commun; 2022 May; 604():158-164. PubMed ID: 35305420
[TBL] [Abstract][Full Text] [Related]
31. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
32. The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma.
Vallejo FA; Shah SS; de Cordoba N; Walters WM; Prince J; Khatib Z; Komotar RJ; Vanni S; Graham RM
J Neurooncol; 2020 Apr; 147(2):317-326. PubMed ID: 32096068
[TBL] [Abstract][Full Text] [Related]
33. Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles.
Zhang Y; Fu X; Jia J; Wikerholmen T; Xi K; Kong Y; Wang J; Chen H; Ma Y; Li Z; Wang C; Qi Q; Thorsen F; Wang J; Cui J; Li X; Ni S
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43408-43421. PubMed ID: 32885649
[TBL] [Abstract][Full Text] [Related]
34. Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme.
da Silveira EF; Chassot JM; Teixeira FC; Azambuja JH; Debom G; Beira FT; Del Pino FA; Lourenço A; Horn AP; Cruz L; Spanevello RM; Braganhol E
Invest New Drugs; 2013 Dec; 31(6):1424-35. PubMed ID: 24072435
[TBL] [Abstract][Full Text] [Related]
35. Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Tivnan A; Heilinger T; Ramsey JM; O'Connor G; Pokorny JL; Sarkaria JN; Stringer BW; Day BW; Boyd AW; Kim EL; Lode HN; Cryan SA; Prehn JH
Oncotarget; 2017 Mar; 8(10):16605-16620. PubMed ID: 28178667
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
37. Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro.
Landis CJ; Zhang S; Benavides GA; Scott SE; Li Y; Redmann M; Tran AN; Otamias A; Darley-Usmar V; Napierala M; Zhang J; Augelli-Szafran CE; Zhang W; Hjelmeland AB
ACS Chem Biol; 2018 Aug; 13(8):2048-2057. PubMed ID: 29905460
[TBL] [Abstract][Full Text] [Related]
38. Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy.
Yang ZZ; Gao W; Liu YJ; Pang N; Qi XR
Mol Pharm; 2017 Apr; 14(4):1012-1022. PubMed ID: 28252970
[TBL] [Abstract][Full Text] [Related]
39. Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy.
Jiang T; Qiao Y; Ruan W; Zhang D; Yang Q; Wang G; Chen Q; Zhu F; Yin J; Zou Y; Qian R; Zheng M; Shi B
Adv Mater; 2021 Nov; 33(45):e2104779. PubMed ID: 34751990
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
